Table 3. Relationship between FLT3 mutation status and disease characteristics.
| Total (%) | ITD | D835Mt | |||||
|---|---|---|---|---|---|---|---|
| + (%) | − (%) | P | + (%) | − (%) | P | ||
| Patients | 25 | 9 (36.0) | 16 (64.0) | 9 (36.0) | 16 (64.0) | ||
| FAB subtype | <0.001 | 0.835 | |||||
| M3 | 20 (80.0) | 4 (44.4) | 16 (100.0) | 7 (77.8) | 13 (81.3) | ||
| M3v | 5 (20.0) | 5 (55.6) | 0 (0) | 2 (22.2) | 3 (18.8) | ||
| PML/RARα isoform | 0.008 | 0.821 | |||||
| Long/bcr1 | 13 (52.0) | 1 (11.1) | 12 (75.0) | 4 (44.4) | 9 (56.3) | ||
| Short/bcr3 | 10 (40.0) | 7 (77.8) | 3 (18.8) | 4 (44.4) | 6 (37.5) | ||
| Variable/bcr2 | 2 (8.0) | 1 (11.1) | 1 (6.3) | 1 (11.1) | 1 (6.3) | ||
| Surface markers | |||||||
| CD2+ | 10 (40.0) | 9 (100.0) | 1 (6.3) | <0.001 | 2 (22.2) | 8 (50.0) | 0.174 |
| CD34 + | 8 (32.0) | 5 (55.6) | 3 (18.8) | 0.058 | 3 (33.3) | 5 (31.3) | 0.915 |
| CD56 + | 4 (16.0) | 2 (22.2) | 2 (12.5) | 0.525 | 1 (11.1) | 3 (18.8) | 0.617 |
| CD2+34+ | 5 (20.0) | 5 (55.6) | 0 (0) | <0.001 | 2 (22.2) | 3 (18.8) | 0.835 |
| CD2+56 + | 2 (8.0) | 2 (22.2) | 0 (0) | 0.049 | 1 (11.1) | 1 (6.3) | 0.667 |
| CD34+56 + | 2 (8.0) | 1 (11.1) | 1 (6.3) | 0.667 | 1 (11.1) | 1 (6.3) | 0.667 |
| CD2+34+56+ | 1 (4.0) | 1 (11.1) | 0 (0) | 0.174 | 1 (11.1) | 0 (0) | 0.174 |
| CD2or34or56+a | 14 (56.0) | 9 (100.0) | 5 (31.3) | <0.001 | 3 (33.3) | 11 (68.8) | 0.087 |
| TdT + | 7 (28) | 4 (44.4) | 3 (18.8) | 0.170 | 3 (33.3) | 4 (25.0) | 0.656 |
Mean values (minimum to maximum) for FLT3 mRNA. P values were determined with the t test for surface markers, TdT, and FLT3mRNA, and with Fisher's exact test for PML/RARα isoform.
*Incidence of at least one of the three surface markers.